Radhakrishnan Maha 4
4 · Candel Therapeutics, Inc. · Filed Jun 24, 2026
Research Summary
AI-generated summary of this filing
Candel (CADL) Director Radhakrishnan Maha Receives 32,000-Share Option Award
What Happened
Radhakrishnan Maha, a director of Candel Therapeutics, was granted a derivative award for 32,000 shares on June 23, 2026. The filing reports the award at $0.00 per share (total reported value $0) — this is a grant of equity compensation (an award/option-style derivative), not an open‑market purchase or sale.
Key Details
- Transaction date: 2026-06-23; Filing date: 2026-06-24 (timely).
- Reported amount: 32,000 shares (derivative award) at $0.00 per share; total reported value $0.
- Shares owned after the transaction: not specified in the filing.
- Vesting note: award vests upon the earlier of (i) June 23, 2027 or (ii) the next annual meeting of stockholders; vesting stops if the director resigns or ceases service unless the board decides otherwise.
- Transaction code: A (award/grant); derivative transaction (not an immediate cash transaction).
Context
This was a standard equity award for a board member. As a derivative grant, it gives the holder the right to receive or purchase shares in the future if vesting/exercise conditions are met — it does not represent an immediate market purchase or sale. Such director awards are commonly part of routine compensation and do not, by themselves, signal an intent to buy or sell shares in the open market.
Insider Transaction Report
- Award
Stock Option (Right to Buy)
[F1]2026-06-23+32,000→ 32,000 totalExercise: $9.08Exp: 2036-06-23→ Common Stock (32,000 underlying)
Footnotes (1)
- [F1]This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 23, 2027 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the "Board") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting.